Baird lowered the firm’s price target on Regeneron (REGN) to $652 from $759 and keeps a Neutral rating on the shares. The firm said its Eylea ...

This was the stock's third consecutive day of gains.

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Biogen (BIIB – Research Report), with a price ...

This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol ...

US Stock Market Live | Dow Jones | Nasdaq Today | Global markets surged after Trump ruled out firing Fed Chair Powell and ...

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intuitive Surgical (ISRG – Research Report), ...

Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicineHOLLY SPRINGS, N.C., April 23, 2025 -- ...

Regeneron Pharmaceuticals (REGN) has inked a $3B deal with contract drug developer FUJIFILM Diosynth Biotechnologies (FUJIY) ...

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and ...